Cellectis, Servier, Pfizer report Phase I data for CAR T therapy in pediatric B-ALL

Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS), Servier (Neuilly-sur-Seine, France) and Pfizer Inc. (NYSE:PFE) reported preliminary data from five evaluable pediatric patients

Read the full 192 word article

User Sign In